CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative…

View More CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China

Artramedia Expands Its Global Reach With Innovative Tools That Help Storytellers, Filmmakers, and Musicians Build Audiences and Shape Culture Worldwide

Empowering creators with data-driven exposure, licensing, and global audience tools. At Artramedia, we believe that powerful stories don’t need a studio — they need connection.…

View More Artramedia Expands Its Global Reach With Innovative Tools That Help Storytellers, Filmmakers, and Musicians Build Audiences and Shape Culture Worldwide